Where Medical Device Innovation Meets Global Quality Leadership
Haemonetics has appointed Kristen Hastings as Senior Director, strengthening its leadership bench at a critical moment where medical device innovation, regulatory complexity, and patient safety are converging faster than ever.
In an industry defined by life-critical products, quality is not a function. It is the operating system. Kristen’s elevation reflects Haemonetics’ strategic intent to embed quality, risk management, and post-market surveillance directly into the heart of product innovation.
This is not a compliance role.
This is a patient-impact leadership role.
A Career Built at the Intersection of Engineering, Clinical, and Quality
Kristen Hastings brings over two decades of deep medical device leadership, spanning product development, global quality systems, post-market surveillance, and regulatory integration.
Her career journey–from Development Engineer and Clinical Research Associate to global quality system steward–gives her something rare in medtech leadership: end-to-end visibility of the entire product lifecycle.
From early-stage design controls to post-market safety monitoring, Kristen understands not just how devices get built–but how they remain safe, compliant, and trusted long after launch.
Leading Quality in a World of Increasing Regulatory Complexity
Before her Senior Director appointment, Kristen served as Director of Quality – Design, Clinical and Software Quality & Post Market Surveillance at Haemonetics.
Her scope included:
- Global Post Market Surveillance systems
- FDA device reporting and complaint management
- Design Quality leadership across hardware, software, diagnostics, and disposables
- Risk management ownership for new product introduction
- Integration leadership for acquisitions
In parallel, she managed multi-disciplinary teams across design, clinical quality, software quality, and post-market compliance–ensuring that innovation and regulatory rigor moved in lockstep.
In a world shaped by EU MDR, IVDR, FDA scrutiny, and increasing software complexity, this role sits at the center of product survival.
20 Years of Quality Systems Mastery at Boston Scientific
Kristen spent nearly two decades at Boston Scientific, one of the most regulated and complex medtech environments in the world.
Her leadership spanned:
- Global Design Controls & Risk Management
- Corporate Quality Systems
- Post Market Surveillance
- Audit readiness and FDA inspections
- Quality integration for acquisitions
- Design History File compliance across regions
She was not only executing systems.
She was designing the systems that others executed.
Her work helped shape how global risk data, usability engineering, and quality-by-design frameworks operate across entire franchises.
Why This Appointment Matters for Haemonetics
Haemonetics operates in a category where:
- Products are life-critical
- Software and hardware converge
- Regulatory expectations keep rising
- Post-market data defines brand trust
Kristen Hastings brings the exact leadership profile needed for this environment:
- Deep technical credibility
- Systems-level thinking
- Regulatory fluency
- Cross-functional authority
- Patient-centric quality philosophy
Her mandate will likely focus on:
- Embedding quality into product strategy, not just audits
- Scaling global risk management frameworks
- Strengthening post-market intelligence systems
- Ensuring acquisitions integrate without compliance risk
- Building future-ready quality cultures
This is not about avoiding failures.
This is about designing reliability into innovation itself.
CXO Gateway Reflection
At CXO Gateway, we see Kristen Hastings’ appointment as a strategic elevation of quality from a control function to a growth enabler.
In modern medtech:
Innovation without quality is dangerous.
Quality without innovation is irrelevant.
Kristen sits precisely at the intersection of both.
Her leadership represents a new generation of medtech executives–those who understand that the future of healthcare is built not just on breakthrough technology, but on invisible systems of safety, risk, and trust that operate at global scale.